Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer

O. Alhamarneh, J. Murphy, Stephen Atkin, R. J A England

Research output: Contribution to journalArticle

Abstract

Somatostatins are neuropeptides that have a downregulatory effect on various physiological processes. Their use in the management of certain endocrine tumours is well recognized. Their use in thyroid cancer is not established, although there is some evidence to suggest that they have a role in advanced metastatic disease. We report a case of a patient with advanced metastatic follicular thyroid cancer which demonstrated strong octreotide uptake with reduced avidity for I131. Treatment with the somatostatin analogue octreotide, however, failed to achieve a significant response. We feel this case is important as it suggests that although octreotide provides a useful further imaging modality in differentiated thyroid cancer, it has no therapeutic role.

Original languageEnglish
Pages (from-to)653-654
Number of pages2
JournalJournal of Laryngology and Otology
Volume118
Issue number8
DOIs
Publication statusPublished - Aug 2004
Externally publishedYes

Fingerprint

Octreotide
Somatostatin
Thyroid Neoplasms
Physiological Phenomena
Neuropeptides
Therapeutics
Neoplasms

Keywords

  • Somatostatin
  • Thyroid Neoplasms

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer. / Alhamarneh, O.; Murphy, J.; Atkin, Stephen; England, R. J A.

In: Journal of Laryngology and Otology, Vol. 118, No. 8, 08.2004, p. 653-654.

Research output: Contribution to journalArticle

@article{6e0e4b8257634dedb46bbae8f08eb02b,
title = "Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer",
abstract = "Somatostatins are neuropeptides that have a downregulatory effect on various physiological processes. Their use in the management of certain endocrine tumours is well recognized. Their use in thyroid cancer is not established, although there is some evidence to suggest that they have a role in advanced metastatic disease. We report a case of a patient with advanced metastatic follicular thyroid cancer which demonstrated strong octreotide uptake with reduced avidity for I131. Treatment with the somatostatin analogue octreotide, however, failed to achieve a significant response. We feel this case is important as it suggests that although octreotide provides a useful further imaging modality in differentiated thyroid cancer, it has no therapeutic role.",
keywords = "Somatostatin, Thyroid Neoplasms",
author = "O. Alhamarneh and J. Murphy and Stephen Atkin and England, {R. J A}",
year = "2004",
month = "8",
doi = "10.1258/0022215041917853",
language = "English",
volume = "118",
pages = "653--654",
journal = "Journal of Laryngology and Otology",
issn = "0022-2151",
publisher = "Cambridge University Press",
number = "8",

}

TY - JOUR

T1 - Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer

AU - Alhamarneh, O.

AU - Murphy, J.

AU - Atkin, Stephen

AU - England, R. J A

PY - 2004/8

Y1 - 2004/8

N2 - Somatostatins are neuropeptides that have a downregulatory effect on various physiological processes. Their use in the management of certain endocrine tumours is well recognized. Their use in thyroid cancer is not established, although there is some evidence to suggest that they have a role in advanced metastatic disease. We report a case of a patient with advanced metastatic follicular thyroid cancer which demonstrated strong octreotide uptake with reduced avidity for I131. Treatment with the somatostatin analogue octreotide, however, failed to achieve a significant response. We feel this case is important as it suggests that although octreotide provides a useful further imaging modality in differentiated thyroid cancer, it has no therapeutic role.

AB - Somatostatins are neuropeptides that have a downregulatory effect on various physiological processes. Their use in the management of certain endocrine tumours is well recognized. Their use in thyroid cancer is not established, although there is some evidence to suggest that they have a role in advanced metastatic disease. We report a case of a patient with advanced metastatic follicular thyroid cancer which demonstrated strong octreotide uptake with reduced avidity for I131. Treatment with the somatostatin analogue octreotide, however, failed to achieve a significant response. We feel this case is important as it suggests that although octreotide provides a useful further imaging modality in differentiated thyroid cancer, it has no therapeutic role.

KW - Somatostatin

KW - Thyroid Neoplasms

UR - http://www.scopus.com/inward/record.url?scp=4644332284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644332284&partnerID=8YFLogxK

U2 - 10.1258/0022215041917853

DO - 10.1258/0022215041917853

M3 - Article

C2 - 15453947

AN - SCOPUS:4644332284

VL - 118

SP - 653

EP - 654

JO - Journal of Laryngology and Otology

JF - Journal of Laryngology and Otology

SN - 0022-2151

IS - 8

ER -